FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for PolyPid in a report issued on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($4.56) per share for the year, up from their previous forecast of ($4.83). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.79) EPS.

Separately, Craig Hallum assumed coverage on shares of PolyPid in a research report on Monday, November 4th. They set a “buy” rating and a $10.00 price objective on the stock.

PolyPid Trading Up 9.0 %

Shares of NASDAQ:PYPD opened at $3.15 on Monday. The company has a 50 day moving average of $3.24 and a 200-day moving average of $3.51. The firm has a market cap of $15.11 million, a P/E ratio of -0.40 and a beta of 1.33. PolyPid has a twelve month low of $2.37 and a twelve month high of $9.20. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Hedge Funds Weigh In On PolyPid

An institutional investor recently raised its position in PolyPid stock. Rosalind Advisors Inc. lifted its holdings in PolyPid Ltd. (NASDAQ:PYPD) by 62.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 679,168 shares of the company’s stock after acquiring an additional 262,368 shares during the period. PolyPid makes up approximately 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 18th biggest position. Rosalind Advisors Inc. owned approximately 14.16% of PolyPid worth $2,336,000 at the end of the most recent quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.